10
Participants
Start Date
November 1, 2020
Primary Completion Date
April 17, 2023
Study Completion Date
November 1, 2023
Pembrolizumab (Keytruda)
Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
Universitair Medisch Centrum Groningen, Groningen
Merck Sharp & Dohme LLC
INDUSTRY
University Medical Center Groningen
OTHER